Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors


Study Number
567919
Phase
I/II
Age Group
Adult
Purpose

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

Full Title

A PHASE 1/2, OPEN-LABEL, MULTICENTER, NON-RANDOMIZED, SAFETY AND ACTIVITY STUDY OF HER2-TARGETED DUAL SWITCH CAR-T CELLS (BPX-603) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED HER2-POSITIVE SOLID TUMORS

ClinicalTrials.Gov ID
NCT04650451

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.